| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6450H9926N1690O1998S46 |
| Molar mass | 144588.95 g·mol−1 |
 N Y (what is this?) (verify) | |
Sirukumab (INN,USAN) (developmental code nameCNTO-136, tentative brand namePlivensia) is a human monoclonal antibody designed for the treatment ofrheumatoid arthritis.[1] It acts against the proinflammatory cytokineInterleukin 6 (IL-6).[2]
Sirukumab is currently underdevelopment byJohnson & Johnson's subsidiaryCentocor.[3]
It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5]By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
The drug was previously under development for the treatment ofdepression.[7]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
